WALTHAM, MA—Carl Dambkowski, the Chief Medical (TASE:BLWV) Officer of Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE), a $2.2 billion market cap biotech company whose stock has declined nearly 18% year-to-date, has sold 2,725 shares of common stock, according to a recent SEC filing. The shares were sold on May 7, 2025, at a weighted average price of $35.75, resulting in a total transaction value of $97,418.
The sale was conducted under a Rule 10b5-1 trading plan, which Dambkowski adopted on August 21, 2024. Following this transaction, Dambkowski retains direct ownership of 244,448 shares in the company. The shares were sold in multiple transactions with prices ranging from $35.23 to $36.09.
In other recent news, Apogee Therapeutics has been making notable strides in its clinical and business developments. The company recently signed a significant manufacturing agreement with Samsung (KS:005930) Biologics for its drug substance APG777, which will support its clinical development and potential commercial sale. This partnership is a key strategic move for Apogee as it advances its clinical pipeline. Additionally, Apogee’s APG777 is progressing through a Phase II study for Atopic Dermatitis, with results expected by mid-year, which has garnered confidence from analysts.
Stifel analysts maintained a Buy rating with a $95 price target, citing the potential of APG777, especially in light of its successful Phase I data. TD Cowen also reiterated a Buy rating, expressing optimism about Apogee’s clinical developments and the potential of APG777 to expand into treatments for asthma and eosinophilic esophagitis. Meanwhile, Jefferies analyst Akash Tewari raised the price target for Apogee to $86, emphasizing positive outcomes from early-stage trials and the company’s confidence in its drug’s potential. These recent developments highlight Apogee Therapeutics’ continued progress and the positive reception from the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.